Outcomes relied on caregiver-reported behavioral and sleep questionnaires (CBCL, TBAQ-SF, Vineland-2, CSHQ, BISQ), analyzed using mixing effects regression models
Aedes aEgypti microRNA miR-2b regulates ubiquitin-related modifier to control Chikungunya virus replication
You may experience minor bruising around the injection site, but this is usually minimal
Farxiga may also increase the risk of diabetic ketoacidosis, especially in individuals with Type 1 diabetes or those with risk factors (FDA Safety Communication)
Again, orforglipron is still being studied and in late clinical trials, but heres the expected timeline: Eli Lilly plans to submit it to the FDA in late 2025 for approval for weight loss in adults with a BMI of 30 or higher, or 27 and higher with a related health condition